OncoSil Medical Limited
OncoSil Medical Limited (OSL.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for OncoSil Medical Limited (OSL.AX), covering cash flow, earnings, and balance sheets.
OncoSil Medical Limited (OSL.AX) Income Statement & Financial Overview
Explore comprehensive income reports for OncoSil Medical Limited OSL.AX, broken down by year and quarter.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $985383.00 | $428676.00 | $87956.00 | $151352.00 |
| Cost of Revenue | $3.80M | $2.97M | $3.31M | $3.58M |
| Gross Profit | -$3.34M | -$2.54M | -$3.22M | -$3.43M |
| Gross Profit Ratio | -$3.39 | -$5.93 | -$36.65 | -$22.66 |
| R&D Expenses | $1.40M | $1.40M | $1.59M | $1.10M |
| SG&A Expenses | $5.28M | $2.48M | $1.80M | $1.69M |
| Operating Expenses | $6.67M | $3.87M | $3.39M | $2.79M |
| Total Costs & Expenses | $7.66M | $6.88M | $6.71M | $6.37M |
| Interest Income | $0.00 | $11329.00 | $55236.00 | $60754.00 |
| Interest Expense | $0.00 | $0.00 | $5229.00 | $4134.00 |
| Depreciation & Amortization | $12732.00 | -$1140.00 | $84133.00 | $86143.00 |
| EBITDA | -$6.67M | -$6.39M | -$6.48M | -$6.11M |
| EBITDA Ratio | -$6.76 | -$14.91 | -$73.67 | -$40.50 |
| Operating Income | -$6.67M | -$6.42M | -$6.62M | -$6.22M |
| Operating Income Ratio | -$6.77 | -$14.96 | -$75.24 | -$41.07 |
| Other Income/Expenses (Net) | -$558000.00 | $22586.00 | $47991.00 | $18884.00 |
| Income Before Tax | -$7.23M | -$6.39M | -$6.57M | -$6.20M |
| Income Before Tax Ratio | -$7.34 | -$14.91 | -$74.70 | -$40.94 |
| Income Tax Expense | -$526000.00 | -$496000.00 | -$553000.00 | -$506480.00 |
| Net Income | -$6.71M | -$6.36M | -$6.02M | -$5.69M |
| Net Income Ratio | -$6.81 | -$14.83 | -$68.41 | -$37.60 |
| EPS | -$0.17 | -$0.003 | -$0.003 | -$0.004 |
| Diluted EPS | -$0.17 | -$0.003 | -$0.003 | -$0.004 |
| Weighted Avg Shares Outstanding | $39.45M | $2.12B | $2.09B | $1.39B |
| Weighted Avg Shares Outstanding (Diluted) | $39.75M | $2.12B | $2.09B | $1.39B |
Over the last four quarters, OncoSil Medical Limited's revenue moved from $151352.00 in Q4 2023 to $985383.00 in Q2 2025. Operating income in Q2 2025 was -$6.67M, with a strong operating margin of -677%. Despite fluctuations in R&D and SG&A expenses, EBITDA for OncoSil Medical Limited remained robust at -$6.67M, reflecting operational efficiency. Net income dropped to -$6.71M, with an EPS of -$0.17. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan